Effects of Therapy on Urine Neutrophil Gelatinase-Associated Lipocalin in Nondiabetic Glomerular Diseases with Proteinuria

Table 1

Baseline characteristics according to remission status at follow-up.

Baseline characteristics	All patients	By response to treatment		value
		Complete remission	Not in remission
Male, (%)	15 (34.9%)	5 (55.6%)	10 (29.4%)	0.143
Age, years				0.409
BMI, kg/m^2				0.19
Systolic BP, mmHg				0.52
Diastolic BP, mmHg				0.26
ACEI and/or ARB use	38 (88.3%)	8 (80%)	30 (90.9%)	0.52
Corticosteroids ± immunosuppressive agents (%)	25 (58%)	9 (90%)	16 (48.5%)	0.035
Albumin, g/dL	3.14 (0.59–3.88)	1.86 (0.78–3.88)	3.21 (0.59–3.88)	0.035
Cholesterol, mg/dL	250 (143–669)	338 (150–594)	240 (143–669)	0.060
Serum creatinine, mg/dL	1.21 (0.43–4.17)	1.21 (0.54–1.42)	1.21 (0.43–4.17)	0.141
Baseline GFR, mL/min/1.73 m^2	66.2 (12.3–143.4)	77 (54–137)	59 (12–143)	0.09
Proteinuria, g/g creatinine	2.17 (0.09–9.23)	3.06 (0.11–9.23)	2.15 (0.09–9.15)	0.55

Data shown as mean ± SD or median (min–max). considered significant.
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blockade; BMI, body mass index; BP, blood pressure; GFR, glomerular filtration rates.